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OBJECTIVE—Several clinical studies have shown the beneﬁts
of renin-angiotensin system (RAS) blockade in the development
of diabetes, and a local RAS has been identiﬁed in pancreatic
islets. Angiotensin I–converting enzyme (ACE)2, a new compo-
nent of the RAS, has been identiﬁed in the pancreas, but its role
in -cell function remains unknown. Using 8- and 16-week-old
obese db/db mice, we examined the ability of ACE2 to alter
pancreatic -cell function and thereby modulate hyperglycemia.
RESEARCH DESIGN AND METHODS—Both db/db and non-
diabetic lean control (db/m) mice were infected with an adeno-
virus expressing human ACE2 (Ad-hACE2-eGFP) or the control
virus (Ad-eGFP) via injection into the pancreas. Glycemia and
-cell function were assessed 1 week later at the peak of viral
expression.
RESULTS—In 8-week-old db/db mice, Ad-hACE2-eGFP signiﬁ-
cantly improved fasting glycemia, enhanced intraperitoneal glu-
cose tolerance, increased islet insulin content and -cell
proliferation, and reduced -cell apoptosis compared with Ad-
eGFP. ACE2 overexpression had no effect on insulin sensitivity
in comparison with Ad-eGFP treatment in diabetic mice. Angio-
tensin-(1–7) receptor blockade by D-Ala
7–Ang-(1-7) prevented the
ACE2-mediated improvements in intraperitoneal glucose toler-
ance, glycemia, and islet function and also impaired insulin
sensitivity in both Ad-hACE2-eGFP– and Ad-eGFP–treated db/db
mice. D-Ala
7–Ang-(1-7) had no effect on db/m mice. In 16-week-
old diabetic mice, Ad-hACE2-eGFP treatment improved fasting
blood glucose but had no effect on any of the other parameters.
CONCLUSIONS—These ﬁndings identify ACE2 as a novel tar-
get for the prevention of -cell dysfunction and apoptosis occur-
ring in type 2 diabetes. Diabetes 59:2540–2548, 2010
I
n addition to the systemic renin-angiotensin system
(RAS) that regulates blood pressure, the concept of
a tissue RAS, modulating local organ function, is
now well recognized. Accordingly, most organs ex-
press a tissue RAS, capable of locally producing angioten-
sin (Ang)-II (1). A complete tissue RAS has been identiﬁed
in the endocrine and exocrine pancreas, and the expres-
sion of its various components has been demonstrated in
the islets of Langerhans (2–4). While the role of the islet
RAS is not completely understood, recent data suggest
that it may be important in -cell homeostasis and func-
tion. Indeed, it has been shown to be involved in the
regulation of glucose-stimulated insulin secretion, insulin
synthesis (3), and islet blood ﬂow (5). Hyperactivity of the
ACE/Ang-II/AT1 receptor (AT1R) axis of the RAS leads to
a cascade of events implicated in the development of
-cell dysfunction, including the following: increased islet
ﬁbrosis (6), oxidative stress (7,8), and inhibition of proin-
sulin biosynthesis and ﬁrst-phase and glucose-responsive
insulin secretion (3,5,9). Moreover, several studies have
demonstrated the effectiveness of RAS blockade at im-
proving islet morphology and function and reducing islet
oxidative stress (3,5,8,10) (rev. in 11). Recently, angioten-
sin 1–converting enzyme (ACE)2, a captopril-insensitive
ACE homologue, was identiﬁed (12,13) and shown to
cleave Ang-II into the biologically active peptide Ang-(1-7)
(13). Ang-(1-7) properties are mediated by the G-protein–
coupled receptor Mas (14), causing vasodilation, inhibition
of ﬁbrosis (15), stimulation of prostaglandin E (PGE)2
(16), and nitric oxide releases (17). The ACE2/Ang-(1-7)/
Mas axis is hypothesized to act as a negative regulator for
the RAS. Recent data indicate that this alternate pathway
may play a compensatory role in the development of type
2 diabetes. ACE2 protein is elevated in the islets of Zucker
fatty diabetic rats (10), and ACE2 knockout (ACE2
/y)
mice exhibit progressive impairments in glucose tolerance
and reduced ﬁrst-phase insulin secretion (18).
Loss of ﬁrst-phase insulin secretion, an indicator of
pancreatic -cell dysfunction, is considered one of the
earliest insults in type 2 diabetes and is evident before the
onset of impaired glucose tolerance (19). Defects in insu-
lin sensitivity, glucose tolerance, and glucose uptake ex-
hibited by Mas receptor knockout mice (20) further
implicate the loss of Ang-(1-7) signaling in the develop-
ment of type 2 diabetes and metabolic syndrome. We
hypothesized that ACE2 overexpression may ameliorate
glucose homeostasis in diabetic mice and prevent the
development of pancreatic -cell dysfunction. Using leptin
receptor–deﬁcient obese db/db mice, we report that ACE2
overexpression reduced glycemia and increased islet insu-
lin content through Ang-(1-7)–mediated pathways. Our
data conﬁrm the pivotal role of this peptide in the pan-
creas and establish ACE2 as a new target for the treatment
of type 2 diabetes.
RESEARCH DESIGN AND METHODS
Male db/db and nondiabetic (db/m) mice aged 3, 7, and 15 weeks (BKS.Cg-m
/ Lepr
db/J; The Jackson Laboratories, Bar Harbor, ME) were infected with
an adenovirus coding for human ACE2 (hACE2) upstream of an enhanced
green ﬂuorescent protein (eGFP) reporter gene (Ad-hACE2-eGFP) or with the
eGFP virus alone (Ad-eGFP) (21) by direct injection (5  10
7 particle forming
units [pfu] in a total volume of 100 l of 0.9% wt/vol saline) into the pancreas
(n  8/group). The adenovirus was delivered in ﬁve 20-l injections along the
body of the pancreas (Fig. 2A). For a subset of animals, D-Ala
7–Ang-(1-7), an
Ang-(1-7) receptor antagonist, was infused (600 ng  kg
1  min
1  7 days
1)
using mini-osmotic pumps (Durect, Cuppertino, CA) implanted subcutane-
ously at the time of virus injection. All procedures were approved by the
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Determination of ACE2 expression and activity. To prevent protein
degradation, pancreata were ﬁrst incubated in RNAlater stabilization solution
and stored at 80°C. Western blotting for ACE2 expression and ACE2 activity
assays were performed as previously described (21).
Measurements of physiological parameters. To assess glucose metabo-
lism in db/db mice, we performed an intraperitoneal glucose tolerance test
where fasted (12 h) animals were weighed and a bolus intraperitoneal
injection of glucose (2 g/kg) was administered to conscious mice. Blood was
drawn from the catheterized tail vein and analyzed at 0, 15, 30, 60, and 120 min
after glucose administration using a glucometer (Accu-check Aviva; Roche,
Mannheim, Germany).
For determinination of ﬁrst-phase insulin secretion, fasted mice were
anesthetized with isoﬂurane and given a bolus of glucose (1g/kg IP). Blood
samples (50 l) were collected from a catheterized carotid artery at 0, 2, 5, and
10 min following glucose administration. Plasma insulin was then measured
using ELISA (Crystal Chem, Downers Grove, IL).
Insulin sensitivity was analyzed following a 1-h fast, and mice were injected
subcutaneously with human recombinant insulin (0.3 units/kg; Sigma, St
Louis, MO). Blood glucose was measured at 0, 15, 30, 60, and 120 min
following injection.
Fasting blood glucose, glucose tolerance and insulin tolerance were
measured prior to and 7 days after adenovirus administration. The animals
were then killed and the pancreas was removed and rapidly divided, with
one-half ﬁxed in 10% formalin in PBS and the other half frozen in liquid
nitrogen.
Immunohistochemistry. Pancreas sections (5 m) were prepared from 10%
formalin-ﬁxed, parafﬁn-embedded tissue. For antigen unmasking, sections
were incubated in a citrate buffer solution (100 mmol/l citric acid and 100
mmol/l sodium citrate; Sigma) for 13 min at 100°C. Following washes, sections
were incubated for 1 h at room temperature in a blocking solution containing
5% BSA in PBS Tween. Sections were incubated with an anti-insulin primary
antibody (1:100; Abcam, Cambridge, MA) for4ha t4°C, followed by
incubation with biotinylated anti–guinea pig secondary antibody (1:200;
Vector Laboratories, Burlingame, CA) for1ha troom temperature. Sections
were then treated with avidin-biotin complex reagent and developed using
alkaline phosphatase red according to the manufacturer’s protocol (Vector
Laboratories). Pancreatic islet insulin content was calculated as the total
insulin staining per islet area. A total of 20 islets per group (n  6 mice/group)
were analyzed.
Additionally, to determine changes in islet proliferation and apoptosis, we
assessed proliferating cellular nuclear antigen (PCNA) expression and per-
formed terminal deoxynucleotidyl transferase dUTP nick ended labeling
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FIG. 1. Mouse ACE2 expression is elevated in the islets of 8-week-old and reduced in 16-week-old db/db mice. Immunostaining for mACE2 (A)
and quantiﬁcation (B) revealed increased mACE2 expression (brown) in the islets of 8-week-old db/db mice in comparison with db/m. Expression
of mACE2 was signiﬁcantly reduced in the islets of 16-week-old (A [right panel]) vs. 8-week-old (A [left panel]) db/db mice. Representative
Western blot and densitometry (C) demonstrating no signiﬁcant change in pancreatic mACE2 expression in 8-week-old db/m  vs. db/db f mice
and 16-week-old db/m vs. db/db mice. However, reduced mACE2 expression in the pancreas was observed in 16-week-old mice in comparison with
8-week-old mice. Values are expressed as means  SEM. Two-way ANOVA statistical signiﬁcance: †P < 0.05 vs. respective 8-week-old mice and
*P < 0.05 vs. respective db/m mice. (A high-quality digital representation of this ﬁgure is available in the online issue.)
TABLE 1
Baseline metabolic parameters in db/db and db/m mice
8 weeks old 16 weeks old
db/m db/db db/m db/db
Body weight (g) 22.53  0.26 33.65  0.45* 26.08  0.54† 44.06  2.66*‡
Fasting blood glucose (mg/dl) 102.2  5.3 201.0  11.9* 119.8  12.8 398.2  42.8*‡
IPGT AUC (mg  dl
1  min
1) 19.32  2.2 48.41  1.1* 20.42  0.8 76.40  4.6*‡
Data represent baseline parameters of db/m and db/db mice (n  6 per group) prior to infection with Ad-hACE2-eGFP or Ad-eGFP viruses.
Statistical signiﬁcance: *P  0.001 vs. age-matched db/m,† P  0.05 vs. 8-week-old db/m,‡ P  0.001 vs. 8-week-old db/db. IPGT AUC,
intraperitoneal glucose tolerance area under the curve.
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diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2541(TUNEL) staining. These antibodies were incubated simultaneously with
anti-insulin primary antibodies for 36 h at 4°C. Biotinylated anti-goat and
anti-rabbit secondary antibodies (1:200; Vector Laboratories) were incu-
bated at room temperature for 1 h. The sections were then treated with
avidin-biotin complex reagent and developed using 3,3	-diaminobenzidine
(Vector labs). TUNEL staining was performed according to the manufac-
turer’s instructions (Roche, Indianapolis, IN), and the staining was devel-
oped using 3,3	-diamiobenzidine. Image capture was performed using a
Nikon eclipse E600 light microscope. All images were quantiﬁed using
Image-Pro Plus software (Media Cybernetics, Bethesda, MD). For a semi-
quantitative assessment of islet insulin, mouse ACE2 (mACE2), and
hACE2, staining per islet (n  16–20/group) area was used to quantify
protein content from immunohistochemistry (10). For PCNA and TUNEL
staining, positive cells per islet were counted. To assess pancreatic -cell
mass, the mean density of islet insulin staining was multiplied by the mean
islet area per pancreatic section, adjusted for wet organ weight per animal
(six sections per organ) (10).
Statistical analysis. Data are expressed as means  SEM. Data were
analyzed by Student’s t test or two-way ANOVA (Bonferroni post hoc tests to
compare replicate means) when appropriate. Statistical comparisons were
performed using Prism5 (GraphPad Software, San Diego, CA). Differences
were considered statistically signiﬁcant at P  0.05.
RESULTS
Animal model. To address the involvement of ACE2 in
-cell function and the development of type 2 diabetes, we
db/m GFP
db/m ACE2
db/db GFP
db/db ACE2
0
2
4
6
8
* *
h
A
C
E
2
 
s
t
a
i
n
i
n
g
 
(
A
U
)
S
p
l
e
e
n
 
d
u
o
d
e
n
u
m
Liver 
Pancreas 
D
a
y
 
3
D
a
y
 
7
D
a
y
 
1
4
Liver          Pancreas
D
a
y
 
0
E
B
A
C
E
2
 
A
c
t
i
v
i
t
y
 
(
A
U
) C
D
d
b
/
d
b
d
b
/
m
Ad-eGFP        Ad-hACE2-eGFP
A
100
 0             50          100         150
80
0
40
20
60
db/m GFP
db/db GFP
db/db ACE2
db/m ACE2
FIG. 2. Adenovirus-mediated expression of hACE2. A: Schematic of
infection showing Ad-hACE2-eGFP delivery (100 l) by ﬁve microin-
jections along the pancreas. B: Representative immunoﬂuorescence
(n  3) showing Ad-hACE2-eGFP transgene expression in the pancreas
and liver of db/m mice at 0, 3, 7, and 14 days following adenovirus
delivery. Expression of hACE2 peaked at 7 days, as also evidenced by
activity (C) and ACE2 (D and E) immunostaining in the pancreas of
both db/m and db/db mice infected with Ad-hACE2-eGFP. Immuno-
staining for hACE2 revealed high expression in both endocrine and
exocrine tissue (D). E: hACE2 immunostaining in pancreatic islets was
quantiﬁed. Values are expressed as means  SEM. Two-way ANOVA
statistical signiﬁcance: *P < 0.05 vs. Ad-eGFP–treated mice. (A high-
quality digital representation of this ﬁgure is available in the online
issue.)
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FIG. 3. ACE2 overexpression ameliorates glycemic homeostasis.
A: Ad-hACE2-eGFP had no effect on the fasting blood glucose of
8-week-old db/m mice (open bars; n  12). Similarly, the Mas antago-
nist D-Ala
7–Ang-(1-7) (600 ng  kg
1  min
1 subcutaneously) had no
effect on the fasting blood glucose of db/m mice (n  6). Diabetic mice
(solid bars) treated with Ad-eGFP had elevated fasting blood glucose
levels in comparison with db/m mice. Mas blockade did not produce
signiﬁcant changes in the fasting blood glucose of Ad-eGFP–treated
db/db mice. Ad-hACE2 treatment, however, signiﬁcantly reduced fast-
ing blood glucose levels in db/db mice (n  12) to levels not signiﬁ-
cantly different from db/m mice. Mas blockade with D-Ala
7–Ang-(1-7)
prevented ACE2-mediated improvements in fasting blood glucose of
db/db mice. B: Ad-hACE2-eGFP had no effect on the fasting blood
glucose of 16-week-old db/m mice in comparison with Ad-eGFP (n  6).
Ad-hACE2-eGFP infection reduced fasting blood glucose in db/db mice
vs. that in Ad-eGFP–treated mice (n  6). C and E: Glucose tolerance
was determined as the area under the curve (mg  dl
1  min
1) of blood
glucose levels following a bolus of glucose (2g/kg) over a 2-h period.
Ad-hACE2-eGFP delivery had no effect on the glucose tolerance of
db/m mice (open squares) in comparison with Ad-eGFP–treated db/m
mice (open triangles). D-Ala
7–Ang-(1-7) administration had no effect
on Ad-eGFP (open diamonds) or Ad-hACE2-eGFP–treated (open cir-
cles) db/m mice. Ad-eGFP–treated db/db (solid triangles) mice had
signiﬁcantly impaired glucose tolerance that was not affected by Mas
blockade (solid diamonds). Ad-hACE2-eGFP delivery improved glucose
tolerance in diabetic mice (solid squares) in comparison with Ad-
eGFP–treated db/db mice. D-Ala
7–Ang-(1-7) administration attenuated
ACE2-mediated improvements in glucose tolerance in db/db mice
(solid circles). D and F: Ad-ACE2-eGFP delivery had no effect on the
glucose tolerance of 16-week-old db/m mice (open squares) vs. Ad-
eGFP–treated db/m (open triangles) mice. Ad-hACE2-eGFP delivery
failed to improve glucose tolerance in 16-week-old db/db mice (solid
squares) vs. Ad-eGFP—treated db/db mice (solid triangles). Values are
expressed as means  SEM. Two-way ANOVA statistical signiﬁcance:
*P < 0.05 vs. respective db/m;† P < 0.05 vs. db/db GFP; ‡P < 0.05 vs.
db/db ACE2 d-Ala.
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mice. As shown in Table 1, db/db mice weight and fasted
glycemia were signiﬁcantly increased, at both 8 and 16
weeks of age, compared with those of lean db/m mice,
while the ability of db/db mice to metabolize glucose was
dramatically reduced, conﬁrming both obese and diabetic
phenotypes in these animals. In addition, there were no
signiﬁcant differences in pancreatic mACE2 expression
among 8- or 16-week-old db/db and db/m mice. Sixteen-
week-old db/m and db/db mice, however, had lower pan-
creatic mACE2 expression in comparison with respective
8-week old mice (Fig. 1C). Immunohistochemistry (Fig. 1A
and B) revealed increased mACE2 expression in the islets
of Langerhans in 8-week-old db/db compared with db/m
mice. In 16-week-old mice, however, mACE2 expression
was decreased in the islets of db/db compared with those
of 8-week-old db/db mice (Fig. 1A and B). Although not
signiﬁcant, there was a trend toward decreased islet
mACE2 expression in 16-week-old db/db mice in compar-
ison with db/m.
ACE2 viral expression. Following injection of the ade-
novirus (Fig. 2A), hACE2 expression and activity were
assessed at various time points. Immunoﬂuorescence re-
veals that hACE2 expression in the pancreas peaks be-
tween 7 and 14 days after infection (Fig. 2B), as previously
observed in the brain (21). A stronger signal was also
observed in the liver, suggesting that a signiﬁcant amount
of virus is carried out of the pancreas. However, hACE2
expression in the liver disappeared more rapidly, probably
resulting from increased protein turnover in this tissue.
ACE2 activity was signiﬁcantly elevated (Fig. 2C)i nt h e
pancreas of both db/db (slope 69.7  5.9 vs. 8.6  1.8; P 
0.05) and db/m (45.9  4.3 vs. 5.7  1.4; P  0.05) mice
infected with Ad-hACE2-eGFP compared with Ad-eGFP–
infected mice. Morphological analysis of hACE2 immuno-
reactivity showed that the enzyme was expressed in both
exocrine and endocrine pancreas of the db/db and control
mice (Fig. 2D and E) without signiﬁcant difference be-
tween genotypes. Ad-hACE2-eGFP and Ad-eGFP treat-
ments, as well as D-Ala
7–Ang-(1-7) infusion, did not
signiﬁcantly change body weight in either db/db or db/m mice
at either 8 or 16 weeks of age. Adenoviral delivery did not
cause signiﬁcant pancreatic inﬂammation or CD3
 lympho-
cyte inﬁltration (supplemental Fig. 1, available in an online
appendix [http://diabetes.diabetesjournals.org/cgi/content/
full/db09-1297/DC1]).
Glycemic control. Ad-eGFP treatment had no effect on
db/db or db/m fasting blood glucose levels (Fig. 3 A and B)
or glucose tolerance (Fig. 3C and D) at 4 (supplemental
Table 1), 8 (Fig. 3A and C), or 16 weeks (Fig. 3B and D). On
the other hand, ACE2 overexpression signiﬁcantly de-
creased fasting blood glucose in diabetic mice at both 8
(P  0.05) (Fig. 3A) and 16 weeks of age (P  0.05) (Fig.
3B). Ad-hACE2-eGFP improved intraperitoneal glucose
tolerance in 8-week-old (P  0.05) (Fig. 3C and E) but not
16-week-old (Fig. 3D and F) mice. These beneﬁcial effects
of ACE2 were signiﬁcantly prevented following blockade
of the Ang-(1-7) receptor in 8-week-old mice (Fig. 3A and
C). At both 8 and 16 weeks, Ad-hACE2-eGFP had no effect
on insulin sensitivity in comparison with Ad-eGFP–treated
mice (Fig. 4A and B). Ad-hACE2-eGFP signiﬁcantly in-
creased ﬁrst-phase insulin secretion in 8-week-old mice
(Fig. 4C), and this effect was blocked by the Ang-(1-7)
receptor antagonist. ACE2 overexpression also tended to
increase insulin secretion, albeit statistically non-signiﬁ-
cant, in 16-week-old db/db mice (Fig 4D). While glucose
tolerance was impaired in both Ad-eGFP– and Ad-hACE2–
treated 4-week-old mice, Ad-hACE2-eGFP expression had
no effect on glucose tolerance in 4-week-old db/m or db/db
mice. There was not a signiﬁcant difference in insulin
sensitivity of 4-week-old db/m and db/db mice treated with
Ad-eGFP or Ad-hACE2-eGFP. Fasting blood glucose was
signiﬁcantly elevated in Ad-hACE2-eGFP–treated db/db
mice in comparison with Ad-GFP–treated control (supple-
mental Table 1).
Islet insulin content and -cell mass. At 8 and 16 weeks
of age, there were no differences in insulin immunoreac-
tivity between db/m mice treated with the Ad-hACE2-
eGFP or Ad-eGFP. However, Ad-eGFP–treated db/db mice
exhibited reduced insulin staining (Fig. 5A and C). In both
8- (Fig. 5A and C) and 16-week-old (supplemental Fig. 2A
and C) mice, Ad-hACE2-eGFP treatment signiﬁcantly in-
creased the islet insulin content in db/db mice in compar-
ison with that in Ad-eGFP–treated db/db mice. In 8-week-
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FIG. 4. ACE2 overexpression improves insulin secretion but not insu-
lin sensitivity in diabetic mice. Insulin tolerance was expressed by the
area under the curve (mg  dl
1  min
1), measuring blood glucose over
a 2-h period after administration of an insulin bolus (0.3 IU/kg subcu-
taneously). A: 8-week-old diabetic mice (solid bars) had signiﬁcantly
impaired insulin sensitivity in comparison with db/m mice (open bars).
Ad-hACE2-eGFP delivery did not improve insulin sensitivity. D-Ala
7–
Ang-(1-7) (600 ng  kg
1  min
1 subcutaneously) signiﬁcantly wors-
ened insulin tolerance in both Ad-eGFP– and Ad-hACE2-eGFP–treated
db/db mice. B: 16-week-old diabetic mice (solid bars) had signiﬁcantly
impaired glucose tolerance in comparison with db/m mice (open bars).
Ad-hACE2-eGFP delivery had no effect on insulin sensitivity in db/m or
db/db mice vs. respective Ad-eGFP–treated mice. First-phase insulin
secretion was measured as area under the curve (ng  ml
1  min
1)o f
insulin concentration in response to a glucose bolus (1g/kg) over a
10-min period. C: Ad-hACE2-eGFP delivery had no effect on ﬁrst-phase
insulin secretion of 8-week-old db/m mice in comparison with Ad-GFP–
treated db/m mice. ACE2 overexpression signiﬁcantly enhanced insu-
lin secretion in diabetic mice in comparison with Ad-eGFP–treated
db/db mice. Administration of D-Ala
7–Ang-(1-7) attenuated the ACE2-
mediated improvements on ﬁrst-phase insulin secretion. D: ACE2
overexpression did not signiﬁcantly enhance insulin secretion in 16-
week-old db/m mice (open bars) vs. Ad-eGFP treatment. While Ad-
ACE2-eGFP treatment did not signiﬁcantly increase ﬁrst-phase insulin
secretion in db/db mice (solid bars) vs. Ad-eGFP–treated mice, there
was a trend toward enhanced ﬁrst-phase insulin secretion. Values are
expressed as means  SEM. Two-way ANOVA statistical signiﬁcance:
*P < 0.05 vs. respective db/m,† P < 0.05 vs. db/db GFP, and ‡P < 0.05
vs. respective db/db mice treated with D-Ala
7–Ang-(1-7).
S.M. BINDOM AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2543*
†
‡
†
†
†
‡
‡
‡
†
‡‡
D
E F 3
B
e
t
a
 
C
e
l
l
 
M
a
s
s
 
(
n
o
r
m
a
l
i
z
e
d
 
i
s
l
e
t
 
d
e
n
s
i
t
y
 
a
r
e
a
 
p
e
r
 
p
a
n
c
r
e
a
s
 
a
r
e
a
)
C
0
2
4
6
8
10
d
b
/
m
 
G
F
P
d
b
/
m
 
A
C
E
2
+ D-Ala-Ang-(1-7)  + D-Ala-Ang-(1-7) A
2
1
0
B
d
b
/
m
 
A
C
E
2
d
b
/
d
b
 
G
F
P
d
b
/
d
b
 
A
C
E
2
d
b
/
m
 
G
F
P
d
b
/
d
b
 
A
C
E
2
d
b
/
d
b
 
G
F
P
db/m ACE2
db/m ACE2
db/m ACE2
db/m ACE2
db/m GFP d-Ala
db/m GFP d-Ala
db/m GFP d-Ala
db/m GFP d-Ala
db/m GFP
db/m GFP
db/m GFP
db/m GFP
db/db GFP d-Ala
db/db GFP d-Ala
db/db GFP d-Ala
db/db GFP d-Ala
db/m ACE2 d-Ala
db/m ACE2 d-Ala
0
1.0
1.5
0.5
db/m ACE2 d-Ala
db/m ACE2 d-Ala
db/db ACE2
db/db ACE2
db/db ACE2
db/db ACE2
D
o
u
b
l
e
 
i
n
s
u
l
i
n
 
a
n
d
 
P
C
N
A
 
s
t
a
i
n
e
d
 
i
s
l
e
t
s
 
(
p
o
s
i
t
i
v
e
 
c
e
l
l
s
/
i
s
l
e
t
)
0
1
2
3
db/db ACE2 d-Ala
db/db ACE2 d-Ala
db/db ACE2 d-Ala
db/db ACE2 d-Ala
T
(
n
o
r
m
a
l
i
z
e
d
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
 
/
 
i
s
l
e
t
)
u
n
n
e
l
 
s
t
a
i
n
i
n
g
 
I
n
s
u
l
i
n
 
S
t
a
i
n
i
n
g
 
(
S
t
a
i
n
i
n
g
 
D
e
n
s
i
t
y
/
 
I
s
l
e
t
 
A
r
e
a
)
db/db GFP
db/db GFP
db/db GFP
db/db GFP
FIG. 5. ACE2 overexpression enhances islet insulin content and pancreatic -cell proliferation and reduces apoptosis. A: Representative
immunostaining for PCNA (3,3-diaminobenzidine) and insulin (alkaline phosphatase red) (n  15). B: Representative TUNEL staining (n  18).
C: Ad-hACE2-eGFP had no effect on islet insulin content (insulin staining/islet area) in 8-week-old db/m mice (open bars) vs. Ad-eGFP treatment.
D-Ala
7–Ang-(1-7) (600 ng  kg
1  min
1 subcutaneously) administration had no effect on islet insulin content in db/m mice. Ad-eGFP–treated db/db
mice (solid bars) had signiﬁcantly reduced islets insulin content vs. db/m mice, which was unaffected by Mas blockade. Ad-hACE2-eGFP increased
islet insulin content in db/db mice vs. Ad-eGFP–treated mice. Islet insulin content in Ad-hACE2-eGFP–treated db/db mice was not signiﬁcantly
different from that in db/m mice. D-Ala
7–Ang-(1-7) administration signiﬁcantly reduced ACE2-mediated increases in islet insulin content.
However, islet insulin content of D-Ala
7–Ang-(1-7)– and Ad-hACE2–treated mice was not signiﬁcantly different from that of db/m mice. D:
proliferating pancreatic -cells were determined as cells staining positive for both insulin and PCNA. Ad-hACE2-eGFP signiﬁcantly increased
pancreatic -cell proliferation in both db/m and db/db mice in comparison with their respective Ad-eGFP–treated controls. Administration of
D-Ala
7–Ang-(1-7) signiﬁcantly attenuated ACE2-mediated stimulation of pancreatic -cell proliferation. E: Neither Ad-hACE2-eGFP nor Mas
blockade treatment modiﬁed apoptosis in db/m mice. Ad-eGFP–treated db/db mice had no signiﬁcant increase in apoptosis in comparision with
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7–Ang-(1-7) treatment prevented
ACE2-mediated increases in islet insulin content (Fig. 5A
and C). Ad-hACE2-eGFP expression resulted in increased
pancreatic -cell mass in db/m mice. D-Ala–Ang-(1-7) treat-
ment resulted in signiﬁcantly less pancreatic -cell mass in
Ad-ACE2-eGFP–treated mice. While there was a trend
toward increased pancreatic -cell mass in 8- and 16-week-
old db/db mice, this ﬁnding was not statistically signiﬁcant.
Similarly, while there was a trend toward decreased
pancreatic -cell mass in D-Ala–Ang-(1-7)–treated mice,
this difference was not statistically signiﬁcant in Ad-eGFP–
expressing mice (Fig. 5E).
Islet cell proliferation and apoptosis. In both db/m and
db/db mice, Ad-hACE2-eGFP expression increased prolif-
eration of pancreatic -cells (Fig. 5D), as evidenced by the
increase in double-stained cells for insulin and PCNA (Fig.
5A). D-Ala
7–Ang-(1-7) treatment prevented ACE2-mediated
increase in -cell proliferation (Fig. 5A and D). At 8 weeks
of age, there was no signiﬁcant change in apoptosis in
Ad-eGFP–treated db/db mice compared with db/m mice.
ACE2 overexpression and D-Ala
7–Ang-(1-7) treatment had
no effect on apoptosis in db/m mice in comparison with
their Ad-eGFP–treated counterparts (Fig. 5B and E). ACE2
overexpression did, however, signiﬁcantly reduce apopto-
sis in db/db mice in comparison with the Ad-eGFP–treated
group (1.18  0.07 vs. 0.55  0.06, normalized ratio
positive nuclei to total nuclei per islet, P  0.05; n  12),
and this improvement was prevented by Ang-(1-7) recep-
tor blockade (1.16  0.08, P  0.05; n  12) in Ad-hACE2-
eGFP–treated db/db mice. In 16-week-old mice, Ad-hACE2-
eGFP expression in db/db mice did not signiﬁcantly
improve pancreatic -cell proliferation or apoptosis rates
in comparison with Ad-GFP–treated db/db mice (supple-
mental Fig. 2).
DISCUSSION
All the classic components of the RAS (renin, angio-
tensinogen, ACE, and Ang-II type 1 and 2 receptors) have
been identiﬁed in the pancreas, where they are thought to
modulate -cell function (3,4). Several studies implicate
RAS overactivity in the development of islet dysfunction
(8,10). Notably, in vitro (22.2 mmol/l glucose) and genetic
(Zucker diabetic fatty rat) models of type 2 diabetes show
increased expression of ACE and AT1R in islets, support-
ing the idea of a feed-forward mechanism ultimately
resulting in -cell dysfunction (7,10). While ACE2 has been
shown to be elevated in renal tubules and cortex of db/db
mice, prior to the onset of diabetic nephropathy (22), its
relationship with -cell function has not been studied. Our
study shows the following: 1) islet ACE2 expression is
upregulated at 8 weeks and tends to be reduced at 16
weeks of age in db/db mice islets compared with db/m
controls; 2) Ad-hACE2-eGFP signiﬁcantly increased ACE2
expression and activity in the mouse pancreas; 3) ACE2
overexpression was associated with reduced hyperglyce-
mia, improved glucose tolerance, increased insulin secre-
tion and -cell proliferation, and reduced apoptosis in
8-week-old db/db mice; and 4) the beneﬁcial effects of
ACE2 overexpression were prevented by Ang-(1-7) recep-
tor blockade, suggesting that the favorable effects of ACE2
on -cell function are mediated by the Ang-(1-7) peptide.
db/db mice, a classic model of type 2 diabetes, have
previously been reported to have early increase (22) and
late decrease (23) in renal ACE2 expression during dia-
betic nephropathy. These observations are consistent with
our data showing that ACE2 levels in the islets are
increased in 8-week-old but decreased in 16-week-old
db/db mice, in comparison with age-matched db/m mice,
and support our hypothesis that ACE2 may be part of a
compensatory mechanism during -cell dysfunction (11).
In addition, our observations supply a rationale for ACE2
gene therapy in the pancreas. Our experiments were
performed in the C57BLKS/J background of db/db mice.
These mice are obese at 4 weeks of age and develop
persistant hyperglycemia and diabetes between 4 and 8
weeks of age. It is well known that islet compensation
peaks in these animals between 8 and 12 weeks of age and
that -cell failure occurs between 5 and 8 months of age
(24). We therefore studied 4-, 8- and 16-week-old db/db
mice to determine the effects of ACE2 on islets prior to
and during compensation and in decompensated islets.
Adenoviral vectors are a useful tool for gene delivery in
endocrine cells because of their ability to transfer genes
with high efﬁciency to both dividing and nondividing cells
(25). While these tools may be desirable in treatment of
diabetes as a result of their ability to preferentially infect
pancreatic -cells over 
-cells (26), the method has been
limited by evidence of signiﬁcant inﬂammation, tissue
damage, and short duration of viral expression (27,28).
Adenoviral delivery directly into the pancreas and infusion
through the common bile duct at the entrance of the
duodenum have been shown to be effective methods,
although both induce acute pancreatitis, the severity of
which correlates to viral load (27). Alternatively, systemic
adenoviral delivery in mice, with clamped hepatic circula-
tion, does not induce inﬂammation while providing high
levels of viral infection. However, because isolation of the
bile duct and hepatic vasculature resulted in signiﬁcantly
increased mortality in db/db mice, we opted for direct
injection underneath the pancreas capsule. In our hands,
adenovirus administration did not result in the develop-
ment of inﬂammation and there was only minor CD3
 cell
inﬁltration (supplemental Fig. 1), consistent with previous
observations that this adenoviral backbone induced mild
inﬁltration of CD-3 F4/80 into the brain without causing
tissue or cellular damage (29). Therefore, this particular
viral vector may be less immunogenic than those used by
other groups (27,28).
We hypothesized that ACE2 overexpression would ame-
liorate the impaired glucose homeostasis in diabetic mice.
The current study demonstrates that ACE2 reduces fasting
blood glucose and improves glucose tolerance in this
model. Glucose tolerance is determined by both insulin
secretion and peripheral insulin sensitivity. Insulin secre-
tion has been hypothesized to be a more important factor
than insulin sensitivity in determining glucose tolerance
db/m controls. ACE2 overexpression, however, reduced apoptosis in db/db mice vs. Ad-eGFP–treated mice. While D-Ala
7–Ang-(1-7) had no effect
on apoptosis in Ad-eGFP-treated db/db mice, it prevented ACE2-mediated reduction of apoptosis. F: Ad-hACE2-eGFP expression resulted in
signiﬁcant increases in pancreatic -cell mass in db/m mice and trended toward an increase in pancreatic -cell mass in db/db mice. While
D-Ala
7–Ang-(1-7) treatment did not signiﬁcantly reduce pancreatic -cell mass in Ad-eGFP–expressing mice, it prevented ACE2-mediated
enhancement of pancreatic -cell mass. Values are expressed as means  SEM. Two-way ANOVA statistical signiﬁcance: *P < 0.05 vs. respective
db/m,† P < 0.05 vs. respective mice treated with Ad-eGFP, ‡P < 0.05 vs. respective mice treated with D-Ala
7–Ang-(1-7). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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measure of pancreatic -cell function. Moreover, impair-
ment in ﬁrst-phase insulin secretion is a sensitive marker
for reduced pancreatic -cell function and is evident
before the onset of type 2 diabetes (19). Interestingly,
there is signiﬁcant evidence to implicate the ACE2/Ang-(1-
7)/Mas axis in the prevention of insulin resistance. Mas-
deﬁcient mice develop a metabolic syndrome–like state
that includes hyperinsulinemia and impaired glucose tol-
erance (20). Moreover, a recent study demonstrated that
Ang-(1-7) prevents fructose-induced insulin resistance by
stimulating phosphorylation of the insulin receptor, the
insulin receptor substrate-1, and activation of Akt and
phosphatidylinositol 3-kinase (31). In our study, ACE2
overexpression had no effect on insulin tolerance but
increased ﬁrst phase-insulin secretion, suggesting an im-
provement of -cell function rather than insulin sensitiv-
ity. These ﬁndings are supported by another study
showing that loss of ACE2 had no effect on insulin
sensitivity but impaired ﬁrst-phase insulin secretion (18).
These data demonstrate that the primary effect of ACE2
overexpression in the pancreas and liver was mediated by
changes in islet function and not hepatic insulin sensitiv-
ity. Of particular interest, Ang-(1-7) receptor inhibition
worsened insulin sensitivity in all db/db mice. An explana-
tion for this effect is that while our adenovirus was not
expressed in the skeletal muscle or adipose tissue, D-Ala
7–
Ang-(1-7) was administered systemically and therefore
would be expected to reduce insulin signaling in all
tissues, thus worsening insulin sensitivity.
Pancreatic -cell decompensation and death occur dur-
ing the progression of type 2 diabetes. While traditionally
glucotoxicity- and lipotoxicity-mediated oxidative stress
have been hypothesized to be the cause of -cell death in
type 2 diabetes (32), ACE inhibitors and AT1R blockers
enhance islet insulin content in both Zucker diabetic fatty
rats and db/db mice and prevent pancreatic -cell loss,
independently of changes in plasma glucose levels, by
reducing intraislet apoptosis and enhancing pancreatic
-cell proliferation (10,33) Here, ACE2 overexpression
increased islet insulin content in db/db mice above the
level observed in db/m mice. In addition, we found that the
enhanced insulin content, in db/db mice overexpressing
ACE2, was due to enhanced pancreatic -cell proliferation
and reduced apoptosis. We found an increase in pancre-
atic -cell mass in db/m and a trend toward increased
pancreatic -cell mass in db/db mice, supporting the
hypothesis that ACE2 enhances pancreatic -cell prolifer-
ation. While increases in -cell mass were not found in
db/db mice, we hypothesize that a long-term ACE2 expres-
sion model would demonstrate maintained or enhanced
pancreatic -cell mass. The main function of ACE2 is to
transform Ang-II into Ang-(1-7), whose antiproliferative
effects have been demonstrated in tumor growth (34),
cardiac remodeling, and vascular injury (35). Conse-
quently, ACE2 might be expected to have antiproliferative
effects on pancreatic -cells. Although our data showing
that, in both lean and diabetic mice, ACE2 stimulates
-cell proliferation may seem paradoxical at ﬁrst, a very
recent study described the ability of Ang-(1-7) to activate
growth-stimulatory pathways in human mesangial cells
(36). Moreover, Ang-(1-7) has been implicated in the
beneﬁcial effects of both AT1R blockers (37) and ACE
inhibitors (38). RAS blockade has also been reported to
stimulate pancreatic -cell proliferation (10). Accordingly,
these data suggest that enhanced Ang-(1-7) and reduction
of Ang-II signaling may be a putative mechanism for the
increase in pancreatic -cell proliferation associated with
ACE2 overexpression. Alternatively, while the direct ef-
fects of ACE2 on downstream cell signaling are unknown,
the enzyme shares 47.8% sequence homology with collec-
trin (39) which enhances insulin exocytosis (40), stimu-
lates pancreatic -cell proliferation, and increases islet
insulin content (41). ACE2 may therefore act similarly to
collectrin in stimulating pancreatic -cell proliferation,
although the mechanism remains unknown.
Very little is known about the role of ACE2 and Ang-
(1-7) in the regulation of apoptosis. Mas knockout mice
have increased cardiac apoptosis in comparison with
controls (42). Moreover, left ventricular device–mediated
enhancement of ACE2 activity, in end-stage heart failure,
has been associated with reduced myocyte apoptosis in
vivo, and Ang-(1-7)/Mas activation has been shown to
reduce cardiomyocyte apoptosis in vitro (43). Moreover,
oxidative stress directly induces pancreatic -cell death. A
recent study by Chu and Leung demonstrated that ACE
inhibition causes a reduction in intraislet apoptosis and
enhances pancreatic -cell proliferation as a result of
reduced uncoupling protein-2–driven oxidative stress
(44). ACE2, therefore, may preserve pancreatic -cell
mass by reducing oxidative stress. Consistent with these
observations, we show that ACE2 overexpression reduced
apoptosis in 8-week-old diabetic mice. Moreover, we dem-
onstrated that Ang-(1-7) receptor inhibition prevented the
ACE2-mediated reduction in apoptosis, indicating that the
antiapoptotic effects of ACE2 on pancreatic -cells are
mediated by Ang-(1-7). Although not the focus of this
study, ACE2 could potentially regulate several pathways
involved in apoptosis, including uncoupling protein 2 (44),
bradykinin (45), extracellular signal–regulated kinase 1/2
and p38 signaling (46), and Akt phosphorylation (47).
While a decrease in fasting blood glucose was observed in
16-week-old db/db mice, there were no signiﬁcant changes
regarding glucose tolerance, insulin secretion, or insulin
sensitivity. Moreover, despite increased islet insulin con-
tent after ACE2 overexpression, there was not a signiﬁcant
increase in pancreatic -cell mass, proliferation, or apo-
ptosis. Taken together, these data indicate that ACE2
overexpression is not able to rescue -cell function in late
type 2 diabetes. During the pre-diabetic state, pancreatic
-cells undergo a compensatory phase during which -cell
mass and insulin output increase (48); then, at the onset of
hyperglycemia, up to 50–75% of -cell secretory function
is lost (49). Finally, in late type 2 diabetes, pancreatic
-cells undergo decompensation, which results in loss of
up to 60% of -cell mass and failure (48). Given that
signiﬁcant loss of -cell function and mass, added to
deleterious changes in islet morphology, is evident in
15-week-old db/db mice, it is conceivable that ACE2 over-
expression might be too late to reverse these changes.
Indeed, a hypothetical window during which -cell func-
tion and islet morphology can be modiﬁed has been
proposed to exist before the onset of hyperglycemia (50).
ACE2 overexpression for 7 days did, however, increase
islet insulin content and reduce fasting blood glucose.
While we did not see a signiﬁcant effect of ACE2 overex-
pression in 4-week-old mice, these animals have only mild
hyperglycemia and impaired glucose tolerance. We hy-
pothesize that longer ACE2 overexpression may have
resulted in enhanced -cell function. In light of the in-
creased -cell proliferation and reduced apoptosis follow-
ing administration of the adenovirus during the peak of
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apy either before the onset of hyperglycemia or in the
early stages of type 2 diabetes may potentially result in
improved islet function and glucose homeostasis at 16
weeks of age through maintenance of islet compensation.
In summary, islet ACE2 expression increased early and
decreased late in type 2 diabetes. This is consistent with
observations in the diabetic kidney, where ACE2 is
thought to act as a compensatory mechanism for hyper-
glycemia-induced RAS activation. In the db/db mouse
model, ACE2 overexpression signiﬁcantly improved glu-
cose tolerance, enhanced islet function, increased -cell
proliferation and insulin content, and prevented -cell
apoptosis in 8-week-old db/db mice. These ﬁndings suggest
that ACE2 gene therapy could be a novel therapeutic
approach for prevention of -cell dysfunction and loss in
type 2 diabetes.
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